Development of glycopeptide-intermediate resistance by Staphylococcus aureus leads to attenuated infectivity in a rat model of endocarditis

Microbial Pathogenesis

Volumn 45, Issue 5-6, 2008, Pages 408-414

  Majcherczyk, Paul A ^a   Barblan, Jean Luc ^a   Moreillon, Philippe ^a   Entenza, José M ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Endocarditis; Fitness; GISA; Virulence

Indexed keywords

FIBRINOGEN; FIBRONECTIN; GLYCOPEPTIDE; HEMOLYSIN; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL STRAIN; CELL WALL; COLONY FORMING UNIT; CONTROLLED STUDY; ENDOCARDITIS; IN VITRO STUDY; INOCULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS AUREUS; VEGETATION; VIRULENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; ENDOCARDITIS, BACTERIAL; GLYCOPEPTIDES; MUTATION; RATS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE;

BACTERIA (MICROORGANISMS); RATTUS; STAPHYLOCOCCUS AUREUS;

EID: 56549092126     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2008.09.003     Document Type: Article

References (49)

1. Moreillon P., and Que Y.A. Infective endocarditis. Lancet 363 9403 (2004) 139-149
2. Fowler Jr. V.G., Miro J.M., Hoen B., Cabell C.H., Abrutyn E., Rubinstein E., et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293 (2005) 3012-3021
3. Moreillon P., Entenza J.M., Francioli P., et al. Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect Immun 63 (1995) 4738-4743
4. Que Y.A., Haefliger J.A., Piroth L., et al. Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis. J Exp Med 201 (2005) 1627-1635
5. Cheung A.L., Bayer A.S., Zhang G., et al. Regulation of virulence determinants in vitro and in vivo in Staphylococcus aureus. FEMS Immunol Med Microbiol 40 (2004) 1-9
6. Xiong Y.Q., Willard J., Yeaman M.R., et al. Regulation of Staphylococcus aureus alpha-toxin gene (hla) expression by agr, sarA, and sae in vitro and in experimental infective endocarditis. J Infect Dis 194 (2006) 1267-1275
7. Cheung A.L., Eberhardt K.J., Chung E., et al. Diminished virulence of a sar-/agr- mutant of Staphylococcus aureus in the rabbit model of endocarditis. J Clin Invest 94 (1994) 1815-1822
8. Weidenmaier C., Peschel A., Xiong Y.Q., et al. Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. J Infect Dis 191 (2005) 1771-1777
9. Hiramatsu K., Hanaki H., Ino T., et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40 (1997) 135-136
10. Liu C., and Chambers H.F. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 47 (2003) 3040-3045
11. Appelbaum P.C. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 30 (2007) 398-408
12. Cui L., Ma X., Sato K., et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 41 (2003) 5-14
13. Boyle-Vavra S., Labischinski H., Ebert C.C., et al. A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates. Antimicrob Agents Chemother 45 (2001) 280-287
14. Sieradzki K., and Tomasz A. Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J Bacteriol 185 (2003) 7103-7110
15. Cui L., Murakami H., Kuwahara-Arai K., et al. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 44 (2000) 2276-2285
16. Sieradzki K., and Markiewicz Z. Mechanism of vancomycin resistance in methicillin resistant Staphylococcus aureus. Pol J Microbiol 53 (2004) 207-214
17. Sakoulas G., Eliopoulos G.M., Fowler Jr. V.G., et al. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 49 (2005) 2687-2692
18. Renzoni A., Francois P., Li D., et al. Modulation of fibronectin adhesins and other virulence factors in a teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 48 (2004) 2958-2965
19. Bischoff M., and Berger-Bachi B. Teicoplanin stress-selected mutations increasing sigma(B) activity in Staphylococcus aureus. Antimicrob Agents Chemother 45 (2001) 1714-1720
20. Singh V.K., Schmidt J.L., Jayaswal R.K., and Wilkinson B.J. Impact of sigB mutation on Staphylococcus aureus oxacillin and vancomycin resistance varies with parental background and method of assessment. Int J Antimicrob Agents 21 (2003) 256-261
21. McCallum N., Karauzum H., Getzmann R., et al. In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance. Antimicrob Agents Chemother 50 (2006) 2352-2360
22. Koehl J.L., Muthaiyan A., Jayaswal R.K., et al. Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 48 (2004) 3749-3757
23. Verdier I., Reverdy M.E., Etienne J., et al. Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II. Antimicrob Agents Chemother 48 (2004) 1024-1027
24. Burnie J., Matthews R., Jiman-Fatami A., et al. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin. Clin Infect Dis 31 (2000) 684-689
25. Vaudaux P., Francois P., Berger-Bachi B., and Lew D.P. In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus. J Antimicrob Chemother 47 (2001) 163-170
26. Collins L.V., Kristian S.A., Weidenmaier C., et al. Staphylococcus aureus strains lacking d-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. J Infect Dis 186 (2002) 214-219
27. Linares J. The VISA/GISA problem: therapeutic implications. Clin Microbiol Infect 7 Suppl 4 (2001) 8-15
28. Howden B.P., Ward P.B., Charles P.G., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38 (2004) 521-528
29. Andersson D.I., and Levin B.R. The biological cost of antibiotic resistance. Curr Opin Microbiol 2 (1999) 489-493
30. Ender M., McCallum N., Adhikari R., and Berger-Bachi B. Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus aureus. Antimicrob Agents Chemother 48 (2004) 2295-2297
31. Wichelhaus T.A., Boddinghaus B., Besier S., et al. Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Antimicrob Agents Chemother 46 (2002) 3381-3385
32. Andersson D.I. Persistence of antibiotic resistant bacteria. Curr Opin Microbiol 6 (2003) 452-456
33. Besier S., Ludwig A., Brade V., and Wichelhaus T.A. Compensatory adaptation to the loss of biological fitness associated with acquisition of fusidic acid resistance in Staphylococcus aureus. Antimicrob Agents Chemother 49 (2005) 1426-1431
34. Bottger E.C., Springer B., Pletschette M., and Sander P. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat Med 4 (1998) 1343-1344
35. Sakoulas G., Eliopoulos G.M., Moellering Jr. R.C., et al. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?. J Infect Dis 187 (2003) 929-938
36. Sieradzki K., Roberts R.B., Haber S.W., and Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 340 (1999) 517-523
37. Jarraud S., Lyon G.J., Figueiredo A.M., et al. Exfoliatin-producing strains define a fourth agr specificity group in Staphylococcus aureus. J Bacteriol 182 (2000) 6517-6522
38. Jarraud S., Mougel C., Thioulouse J., et al. Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease. Infect Immun 70 (2002) 631-641
39. Shopsin B., Mathema B., Alcabes P., et al. Prevalence of agr specificity groups among Staphylococcus aureus strains colonizing children and their guardians. J Clin Microbiol 41 (2003) 456-459
40. Haenni M., Majcherczyk P.A., Barblan J.L., and Moreillon P. Mutational analysis of class A and class Bpenicillin-binding proteins in Streptococcus gordonii. Antimicrob Agents Chemother 50 (2006) 4062-4069
41. Reipert A., Ehlert K., Kast T., and Bierbaum G. Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin. Antimicrob Agents Chemother 47 (2003) 568-576
42. Boyle-Vavra S., Challapalli M., and Daum R.S. Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance. Antimicrob Agents Chemother 47 (2003) 2036-2039
43. Entenza J.M., Moreillon P., Senn M.M., et al. Role of sigmaB in the expression of Staphylococcus aureus cell wall adhesins ClfA and FnbA and contribution to infectivity in a rat model of experimental endocarditis. Infect Immun 73 (2005) 990-998
44. Giachino P., Engelmann S., and Bischoff M. Sigma(B) activity depends on RsbU in Staphylococcus aureus. J Bacteriol 183 (2001) 1843-1852
45. Majcherczyk P.A., Rubli E., Heumann D., et al. Teichoic acids are not required for Streptococcus pneumoniae and Staphylococcus aureus cell walls to trigger the release of tumor necrosis factor by peripheral blood monocytes. Infect Immun 71 (2003) 3707-3713
46. Ames B.N., and Dubin D.T. The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid. J Biol Chem 235 (1960) 769-775
47. Heraief E., Glauser M.P., and Freedman L.R. Natural history of aortic valve endocarditis in rats. Infect Immun 37 (1982) 127-131
48. Hall G., Heimdahl A., and Nord C.E. Bacteremia after oral surgery and antibiotic prophylaxis for endocarditis. Clin Infect Dis 29 (1999) 1-8
49. Moreillon P., Francioli P., Overholser D., et al. Mechanisms of successful amoxicillin prophylaxis of experimental endocarditis due to Streptococcus intermedius. J Infect Dis 154 (1986) 801-807